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ABSTRACT 
Background: With no long-term data available in published research to date, this study 
presents details of the swallowing outcomes as well as barriers to, and facilitators of oral 
intake and weight maintenance at 2 years post altered fractionation radiotherapy with 
concomitant boost (AFRT-CB). 
Methods: Twelve patients with T1-T3 oropharyngeal cancer who received AFRT-CB were 
assessed at baseline, 6 months, and 2 years post-treatment for levels of dysphagia and salivary 
toxicity, food and fluid tolerance, functional swallowing outcomes, patient-reported function, 
and weight. At 2 years, participants were also interviewed to explore barriers and facilitators 
of oral intake. 
Results: Outcomes were significantly worse at 2 years when compared to baseline for late 
toxicity, functional swallowing, and patient-rated physical aspects of swallowing. Most 
patients (83%) tolerated a full diet pretreatment, falling to 42% (remainder tolerated soft 
diets) at 2 years. Multiple barriers to oral intake were identified which impacted on activity 
and participation levels. Participants lost 11kg from baseline to 2 years, which was not 
regained between 6 months and 2 years. Global, social, and emotional domains of patient-
reported function returned to pretreatment levels.  
Discussion: At 2 years post AFRT-CB, worsening salivary and dysphagia toxicity, declining 
functional swallowing, and multiple reported ongoing barriers to oral intake, had a negative 
impact on participants’ activity and participation levels relating to eating. These ongoing 
deficits contributed to significant deterioration in physical swallowing functioning determined 
by the MDADI. In contrast, patients perceived their broader functioning had improved at 2 
years, suggesting long-term adjustment to ongoing swallowing deficits.  
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INTRODUCTION 
 
Treatment intensification with altered fractionation radiotherapy (AFRT) for head and neck 
cancer (HNC) has demonstrated improved locoregional control and overall survival compared 
with conventionally fractionated radiotherapy (1). Despite this benefit, AFRT treatment has 
been associated with increased acute toxicity of greater severity and longer duration (2, 3). 
Both the presence of dysphagia and mucositis have been identified in the literature as 
persisting in the early phase post-treatment with AFRT (4-8). Acute toxicity, such as 
mucositis and pain, has been associated with deteriorating functional outcomes known to 
impact on swallowing and mastication (9), resulting in a large proportion of patients requiring 
modified diets and nutritional supplementation (10, 11).  
 
There is, however, currently minimal information available about the extent to which 
dysphagia and associated toxicities persist long-term in the AFRT population. Based on 
radiobiological principles, late-radiation effects are dependent on the total dose and the dose 
per fraction, with larger fraction sizes increasing the risk of severe late effects (4, 12). Hence, 
as a consequence of the reduced dose per fraction used in accelerated radiotherapy regimens, 
late toxicity rates for necrosis, xerostomia, laryngeal edema, skin, and subcutaneous toxicity 
have been found to be significantly less for accelerated regimens compared with conventional 
counterparts post-treatment (7, 8). It is possible then that dysphagia and associated toxicities 
may also be less severe in the long term. However to what extent late effects exist and 
continue to impact on swallowing, nutrition, and patient-rated function at 2 years following 
AFRT, is currently unknown.  
 
Generally, research examining radiotherapy treatment protocols has indicated that patient-
reported function post-treatment is on an upward trajectory with the lowest point immediately 
post-treatment and improving to pretreatment levels within one year (13-18). Whether or not 
this same pattern is evident following AFRT requires further investigation, as few studies to 
date have employed longitudinal study designs which extend to 2 years or more post-
treatment. The preliminary data that is currently available would suggest that significant 
improvements in dysphagia and functional swallowing status can be anticipated in the long 
term (10, 11). Eighteen percent of a heterogenous HNC population who received AFRT 
required alternative feeding due to dysphagia 1-2 months post-treatment (11). However, by 12 
months post-treatment this had improved with only 7% having ongoing significant dysphagia 
(11).  In a more recent study of the impact of AFRT with a concomitant boost (AFRT-CB) in 
a homogeneous group of patients with oropharyngeal cancers, the current research team found 
significant deterioration in functional swallowing, nutrition, and patient-rated functional 
impact from pretreatment to 6 weeks post-treatment, with some recovery (but still below 
pretreatment levels) by 6 months post-treatment (10). This pattern of improvement toward 6 
months post-treatment also concurs with previous research examining quality of life (QoL) 
following a hyperfractionated and accelerated radiotherapy protocol (dose/fraction size <1.5-
1.6Gy), which found improved outcomes at 6 and 12 months post-treatment compared to 
baseline (18). Such data would tend to suggest ongoing improvements in swallowing 
function, swallowing-related toxicity, and patient perspectives of function may be evident in 
the longer term. 
  
Following conventional, hypofractionated, and combined modality radiotherapy treatments 
for HNC, studies have shown that long-term treatment related side effects impact on 
swallowing and nutrition affect QoL and cause distress up to a decade post-treatment (19-22). 
Consequently, as part of understanding the full impact of AFRT on the individual, it is 
important that the extent of any persistent late effects following AFRT treatment and the 
potential impact of these on patient function is better understood. To this end, the aims of the 
current study were to: 1) examine the functional swallowing, nutritional status, and general 
and swallowing-related patient-rated function at 2 years post-treatment with AFRT-CB for 
locally advanced oropharyngeal cancer; and 2) to further explore the patient perspective of 
their ongoing side effects and barriers to oral intake at 2 years post-AFRT.  
 
MATERIALS AND METHODS 
Participants 
Participants were drawn from the Multidisciplinary Head and Neck Clinic at the Princess 
Alexandra Hospital, Brisbane, Australia, following diagnosis of a T1-T3 locally advanced 
squamous cell carcinoma (SCC) of the oropharynx (base of tongue, tonsil, pharyngeal wall, or 
supraglottis [within 1cm of the oropharynx]). Eligible participants were those who 
commenced treatment with curative intent AFRT-CB during a 33 month period ending in 
August 2009. The AFRT-CB regimen involved elective sites being treated to 50Gy in 
2Gy/day over 5 weeks. Known sites of disease received a concomitant boost schedule to a 
total of 66Gy over 5 weeks with an afternoon boost dose (minimum of 6 hours apart) of 
1.6Gy/day in weeks 4 and 5. Ineligible patients were those recommended for surgical or 
multimodality treatment, or had a previous diagnosis of oropharyngeal SCC or any other 
medical condition which may have affected long-term swallowing function (i.e. neurological 
or neurodegenerative disease). Any patient who developed in-field recurrence or subsequent 
neurological or neurodegenerative disease following treatment completion until 2 years post-
treatment was also excluded. All patients received their treatment at the Metro South 
Radiation Oncology Service in Brisbane, Australia. This research was approved by the 
Human Research and Ethics Committees at the Princess Alexandra Hospital, Australia and 
The University of Queensland, and all participants consented to involvement in the study. 
 
The cohort was drawn from that previously reported by Cartmill and colleagues (10). 
Seventeen patients were recommended for treatment with AFRT-CB, and all were eligible for 
recruitment. Of those, 15 participants consented to involvement but only 12 were eligible to 
complete all aspects required for this study. One participant died during treatment of causes 
unrelated to cancer, and 2 participants died between 6 months and 2 years post-treatment; one 
due to local recurrence and post-operative complications and another unrelated to the cancer 
diagnosis. Analysis was conducted on the 12 participants who were eligible for follow-up at 2 
years post-treatment. The mean age at presentation was 66 years (range = 53-82 years, SD = 
20.3) and 83% of participants were male (Table 1). The majority presented with tonsillar 
primaries, node negative neck disease, and 50% had T2 disease. One third of participants 
presented with stage III disease, and one quarter each with stage II and stage IV disease. The 
majority (67%) were current or ex-smokers, and 92% were current drinkers (n = 11).  
 
Procedure 
The current study employed a mixed methodology design to explore both patterns of change 
across time and detailed information of current swallowing status at 2 years post-AFRT. This 
methodology involved collection of toxicity ratings, current dietary tolerance, weight, and 
patient-rated swallowing and general function at baseline, 6 months and again at 2 years post-
treatment. To further examine the patient perspective of their swallowing and nutrition 
function at 2 years post-treatment, participants were contacted via phone to complete a semi-
structured interview.  
 
At baseline, 6 months and 2 years post-treatment, specific toxicity information regarding 
dysphagia and xerostomia was collected using the relevant adverse event (AE) subscales of 
the Common Toxicity Criteria of Adverse Events version 3 (CTCAE v.3). These scales form 
part of the total CTCAE tool, a comprehensive, multimodality toxicity grading schedule that 
scores both acute and late AEs in oncology (23). In this tool, dysphagia is rated on a 5-point 
scale (grade 1- mild, grade 2 - moderate, grade 3 - severe, grade 4 - life threatening or 
disabling, and grade 5 - death related to AE) and xerostomia on only a 3-point scale (grade 1- 
mild, grade 2 - moderate, grade 3 – severe) as this AE is not considered to have a life-
threatening impact or cause death. Toxicity ratings were completed by participants’ treating 
radiation oncologist.  
 
At each time point dietary tolerance was determined based on clinical assessment and patient 
report of food and fluids consumed regularly as part of their dietary routine. Patient 
descriptions of their regular food and fluid consistencies were subsequently re-coded 
consistent with the terminology of the Australian national standards (24) for foods (full, soft, 
minced, pureed, or liquid only) and fluids (thin, mildly thick, moderately thick, and extremely 
thick). This information, and other clinical indicators reported by the patient were used to 
score functional swallowing outcome with the Royal Brisbane Hospital Outcome Measure for 
Swallowing (RBHOMS) (25). The RBHOMS measures everyday performance of swallowing 
function using a 10-part outcome measure scale (25). This scale is clinically valid and 
responsive to changes in swallowing function over time with high levels of sensitivity, 
specificity, and high interrater reliability (25). The scale is divided into four stages of 
swallowing function: 1) nil by mouth; 2) commencing oral intake; 3) establishing oral intake; 
and 4) maintaining oral intake. Each stage is further divided into levels that are described with 
specific clinical features allowing clinicians to differentiate between 10 specific ratings of 
swallow function.  
 
At baseline, and 6 months-post-treatment, weight was collected to the nearest 0.1kg using 
digital scales (G-Tech International GL-6000). Weight was recorded at the same location, 
using the same scales throughout this study, with the exception being at two years post-
treatment, where weight (in kg) was obtained through verbal patient report.  
 
Patients completed the Functional Assessment of Cancer Therapy Additional Concerns for 
Head and Neck Cancer (FACT-H&N) (26) and the M. D. Anderson Dysphagia Inventory 
(MDADI) (27) at baseline, 6 months, and 2 years post-treatment. These questionnaires were 
chosen for their validity and reliability with the HNC population (26, 27). General patient-
perceived function was measured using the FACT-H&N. Four core domains of patient-rated 
function are assessed (physical, social/family, emotional and functional well-being) using 27 
individual items. Twelve additional items assess patient perceptions of treatment-related side 
effects specifically for HNC (26, 28). Patient-rated swallowing function was scored using the 
MDADI. The MDADI contains 20 items that are divided into global, emotional, functional, 
and physical subscales, and scored between 0 (extremely low functioning) to 100 (extremely 
high functioning).  
 
At the 2 year post-treatment time point only, an additional exploration of swallowing function 
was undertaken using a semi-structured patient interview. Interviews were conducted via the 
phone and the interviewer completed real time notations of patient responses. A series of 
questions were used to stimulate discussion around three themes: 1) the presence/absence of 
any ongoing side effects related to treatment; 2) current swallowing, eating and drinking 
function and any strategies used to improve oral intake; and 3) current nutritional status (need 
for nutritional supplements) and any strategies used to improve nutrition. The interviews took 
approximately 30 minutes to complete. During the interview, opportunities were taken to 
clarify and expand on the content of responses with the patient to ensure the nature of their 
reported side effects, and current swallowing and nutrition status were accurately recorded.  
 
Data analysis 
All quantitative data were entered into a Microsoft Excel spreadsheet. Stata version 10 for 
Mac was used for all statistical analysis. Descriptive measures including means and standard 
deviations were recorded for all outcome measures. Two analyses were conducted to compare 
changes in the ordinal data collected for toxicity, swallowing, and patient-rated functional 
impact: 1) change in function from pretreatment to 2 years post-treatment; and 2) change in 
function from 6 months to 2 years post-treatment. Non-parametric Wilcoxon signed rank tests 
were used for both analyses. Change for diet and fluid consistencies tolerated over time was 
measured using chi-square tests. Paired t-tests were used to record change over time points for 
ratio data (e.g. weight). For all statistical comparisons, p < 0.05 was taken to indicate 
statistical significance.  
 
Information obtained from the semi-structured interviews was collated by the interviewing 
clinician (BC) and the patient descriptions of side effects and barriers to oral intake were 
reported as frequency data. This data was then subjected to secondary analysis, with each 
reported side effect or barrier classified using the core set descriptors from the World Health 
Organisation International Classification of Functioning, Disability and Health (ICF) core set 
for HNC (29, 30). The ICF core set for HNC was developed in consensus with 33 
international experts and includes 112 different ICF categories deemed relevant to the specific 
disease condition of HNC (30). Thirty-four categories outline body functions, 33 body 
structures, 26 activities and participation, and 19 contextual environmental factors. Analysis 
of patient responses using this framework was used to gain a more holistic understanding of 
the nature of functional swallowing and nutritional outcomes experienced at 2 years post 
AFRT-CB. Patient responses were coded across all relevant categories, for example, a 
reported presence of “dry mouth” was classified under a body impairment of “salivation”, 
which resulted in an activity limitation in “eating”. It is important to note that exploration of 





Analysis over time revealed a significant worsening in xerostomia (salivary toxicity) and 
swallowing (dysphagia toxicity) as per the CTCAE between pretreatment and 2 years post-
treatment, and 6 months and 2 years post-treatment (Table 2). Statistical comparisons 
revealed that functional swallowing level (as scored by the RBHOMS) at 2 years post-
treatment was significantly reduced in comparison to pretreatment and 6 months post-
treatment (Table 2). Change in functional swallowing ability was not related to fluid intake as 
all participants reported tolerating thin fluids at all time points. However food intake, as 
described by diet tolerance across time points, ranged from a minced diet to a full/normal diet, 
with the proportion of participants tolerating a full diet changing over time. The majority of 
patients (83%) tolerated a full diet pretreatment, which had reduced to 50% at 6 months post-
treatment, and to 42% at 2 years post-treatment. At 6 months post-treatment the remaining 
50% of participants were managing a soft diet, while at 2 years post-treatment 58% reported 
restricting their diet to softer consistencies (i.e. avoiding hard, chewy and dry solids). This 
showed a trend toward significant decline over time (χ2 = 8.43, p = 0.08). Significant weight 
loss was observed from pretreatment to 2 years post-treatment, with a mean 11kg loss during 
this time. Weight did not change significantly from 6 months to 2 years post-treatment (Table 
2). 
 
Analysis of patient-rated functional impact revealed that between pretreatment and 2 years 
post-treatment, participants noted there had been a significant negative impact on their life 
within the physical domain of the MDADI (Table 2). Between 6 months and 2 years post-
treatment there was significant improvement for the head and neck specific domain of the 
FACT-H&N, however there were no other significant findings between pretreatment and 2 
years post-treatment, and 6 months and 2 years post-treatment on either the MDADI or 
FACT-H&N (Table 2).  
 
Outcomes of the semi-structured interviews revealed participants reported 15 barriers to oral 
intake with varying rates of frequency (Figure 1). These barriers were able to be classified 
into 9 categories of body function impairment using the comprehensive ICF core set for HNC. 
The most common patient-reported impairments in bodily functions were classified under 
salivation, energy and drive, taste function, and pharyngeal swallow (Table 3). These 
impairments in body function were also determined to have impact at the activity limitation 
and participation restriction levels. All patient-reported barriers resulted in activity limitations 
and participation restrictions in eating (100%). A smaller proportion of patient-reported 
barriers identified limitation and restrictions in looking after one’s health (2/15) and carrying 
out daily routine (1/15) (Table 3). 
 
Participants were also probed regarding strategies that facilitated the efficiency of their 
swallowing or their eating and drinking experience (Figure 2), and to prevent further weight 
loss at 2 years post-treatment (Figure 3). More than two thirds reported modifying their diet, 
adding fluid to food to assist with swallowing, and avoiding specific foods as strategies to 
manage their swallowing difficulties. Twenty-five percent reported not requiring any 
strategies for swallowing. Regarding strategies to avoid weight loss, over a third reported not 
requiring any strategies to maintain their weight (Figure 3). The remainder reported use of a 
variety of strategies including exercise to improve their appetite, a high protein high energy 
diet, or oral supplements as recommended by their dietitian during treatment (Figure 3).  
 
DISCUSSION 
The current study found a significant deterioration in salivary and swallowing toxicity at 2 
years post-treatment when compared to pretreatment and 6 months post-treatment levels. As 
would be expected, this ongoing toxicity impacted on functional swallowing with the majority 
of the current cohort limiting their diet to soft foods. The current data supports that further 
declines in swallowing function at 2 years following the AFRT-CB protocol can be 
anticipated, and thus long-term monitoring of swallowing function in this population is 
warranted.  
 
While there may be an absence of data specifically relating to the AFRT-CB protocol 
outcomes at 2 years post-treatment, results from other definitive non-surgical treatment 
regimens have reported an ongoing functional impact on swallowing and nutrition long-term 
post-treatment (31-35). Studies have found that between 5 and 50% of participants are able to 
tolerate a full diet without restrictions at 1-2 years post-treatment with previously examined 
radiotherapy protocols for HNC (17, 36-38). The prevalence rate for impaired function 
observed in the current study is therefore at the high end (42%) of the expected long-term 
swallowing outcomes from other protocols. Although not specifically assessing dietary 
tolerance but perhaps an indicator of functional outcomes, concomitant boost protocols have 
been associated with a greater incidence of long-term dysphagia, as measured by incidence of 
aspiration pneumonia, feeding tube dependence, or stricture (39).  
   
The long-term deficits in swallowing function observed following definitive non-surgical 
treatment for HNC have been attributed to late treatment effects including tissue atrophy, 
oedema, and fibrosis (32-34). Hence the reason for deterioration in toxicity and subsequent 
impact on functional swallowing and weight in the current cohort may be the result of similar 
late or chronic effects of the AFRT-CB protocol. However research has also demonstrated 
that late reactions following radiotherapy treatment are not only caused by the radiobiological 
dose to tissues, but can also be linked to the extent and duration of acute cellular mucosal 
depletion, as is found in accelerated and hyperfractionated regimens (4). Where such late 
mucosal reactions may occur in part as a consequence of a severe acute reaction (40), this has 
been referred to as “consequential” late toxicity. The underlying premise of AFRT is that 
through the use of smaller fraction sizes it is possible to reduce the impact of tumour cell 
repopulation, thus improving cell kill, but without increasing late toxicity. However it is well 
recognised that this form of treatment results in heightened acute toxicity (4) and hence, the 
potential for consequential late effects. Although it is impossible to make any definitive 
statements regarding the cause of the declining function observed in the current study, it is 
possible that the factors contributing to the observed decline in swallowing and salivary 
toxicity in the current cohort may be a combination of both “true” and/or “consequential” late 
effects of treatment (4, 5).   
 The nature of the long-term swallowing deficits reported in this study appears to be 
comparable to previous populations studied. Although the current study did not objectively 
assess function using videofluoroscopy, 75% of patients reported “food sticking in their 
throat”, and 50% reported “coughing with food and/or fluid”. These patient descriptions most 
likely relate to the presence of pharyngeal residue and penetration/aspiration which have been 
identified as key physiological deficits present in the long-term following treatment in 
heterogenous HNC populations studied (33, 34).  The current data, however, does differ from 
most other radiotherapy research in relation to the pattern of declining function in the long-
term, with the prevalence of swallowing difficulty in the current cohort observed to increase 
from 6 months to 2 years. This pattern of declining function over time also differs to the 
general pattern of improving swallowing outcomes reported by Yu et al. (2005) following 
AFRT. The differences found in results of the current study could be attributed to the 
retrospective nature of data collection, and the use of a crude rating scale to measure 
dysphagia in the Yu et al. (2005) study. However, equally it is acknowledged that there is 
currently minimal data specific to the AFRT-CB population available for comparison and 
further research is needed to confirm the current pattern of long-term declining function as 
observed in the current cohort.    
 
Using the ICF framework, the functional swallowing and ongoing barriers to oral intake 
reported by participants at 2 years post-treatment were observed to primarily contribute to 
activity limitation and participation restriction relating to eating. Previous studies have linked 
impairments in body functions to activity limitations in eating, although without formally 
using the ICF framework. Ku et al. (2007) reported 90% of their heterogenous HNC cohort 
who received CRT reported a dry mouth (impairment in body function) at 12 months post-
treatment, and this coincided with 100% alternating food and fluid boluses (eating limitation), 
and more than 80% avoiding specific foods in their diet (eating limitation) (41). Oral pain, 
mouth sores, taste changes, oral dryness, and loss of appetite have previously been reported as 
side effects which heighten awareness of functional swallowing difficulties (42, 43). Long-
term xerostomia has been postulated as impacting on functional swallowing by decreasing 
bolus lubrication, and increasing bolus transit time (34), and has been reported by over 90% 
of the current cohort.  
 
Fatigue and appetite were two patient-reported barriers to oral intake that were classified as 
impairments body functions for energy and drive (appetite and energy level subcategories). 
These impairments resulted in activity limitations and participation restrictions regarding 
looking after one’s health and carrying out a daily routine, as well as eating. Previous 
literature has reported these impairments under social functioning, and work and day to day 
tasks (44). One of the restrictions to using the ICF framework is in the classification of 
enjoyment or pleasure regarding eating and drinking activity and participation, which could 
be classified under emotional functioning, or as a contextual factor. Despite participants being 
able to participate in eating and drinking activities, there is no current classification that 
outlines whether participation is enjoyable or not. For many HNC patients, not only is the act 
of eating made difficult as a result of treatment side effects, but the act of enjoyment or 
gaining pleasure from eating is also impaired, possibly resulting in poor nutrition, weight loss, 
and social isolation. 
 
The current cohort described using a number of strategies to facilitate eating, which included 
dietary (modifying diet, avoiding specific foods), mealtime (alternating food/fluid boluses), 
and physiological (multiple swallows to clear residue, using salivary substitutes to alleviate 
the impact of a dry mouth during meals) facilitators. Each individual reported the use of 
multiple strategies to assist intake, and those which were most effective for each individual 
varied between patients. “Active planning’ and the use of  “trial and error” relating to 
strategies regarding food selection, consistency, preparation, caloric density, and the physical 
act of eating have similarly been described in heterogenous HNC populations (43-45). The 
information obtained from further, comprehensive study of patient strategies may help in the 
future to further optimise patient adjustment to the swallowing changes which continue in the 
long term post treatment.   
 
Despite worsening functional swallowing, and perhaps as a result of these mealtime 
strategies, participants’ weight remained stable between 6 months and 2 years post-treatment. 
Interestingly, fewer participants reported strategies to maintain their weight versus strategies 
to improve their swallowing, and this may have had an impact on participants’ ability to 
regain lost weight between 6 months and 2 years post-treatment. In contrast, the lack of 
strategies to maintain weight may reflect the patient perspective that weight was no longer a 
concern to the study cohort. In the absence of data regarding each patient’s personal goal 
weight it is not possible to determine how many chose to remain at the lower post-treatment 
weight and how many were unable to intentionally regain the weight they had lost.  
 
Reflecting the decline in swallowing function and its impact on activity and participation 
levels observed at 2 years, the patients self ratings for the physical component of the MDADI 
were found to reveal a significant deterioration between pretreatment and 2 years post-
treatment. The results of this specific patient-rated physical domain of swallowing at 2 years 
post AFRT-CB is in contrast with the previously reported data for heterogenous HNC patients 
which have reported improving global function on the EORTC-QLQ-C30 scale by 12 months 
post-treatment (13-17). Furthermore, overall patient-rated functional outcomes (using the 
FACT-H&N) have also been found improve to pretreatment levels by 12 months post-
treatment following a hyperfractionated , accelerated regimen (18).   Examination of the 
physical components of the MDADI for the current cohort revealed a significant long-term 
concern regarding the ongoing limitations to the foods they could eat, and increased effort and 
time to complete meals. 
 
Despite patients reporting some specific concerns, the remaining data from the broader 
functioning domains of the MDADI and FACT-H&N assessments revealed that patients 
perceptions of their levels of general function had returned to pretreatment levels by 2 years 
post-treatment. This pattern of long term adjustment has been found previously (13-18). In the 
current cohort, head and neck specific concerns such as cosmesis, voice and communication, 
and the presence of pain significantly improved from 6 months to 2 years post-treatment. The 
results from the current study reveal that for patients undergoing AFRT-CB, broadly speaking 
patient-rated function continues the upward trajectory of improvement post-treatment. In the 
absence of improvement in toxicity and functional swallowing, this finding may be an 
indication of patient adjustment to the ongoing deficits caused by HNC and its treatment (27, 
46-48). 
 
While the current study is the first to provide information on long term outcomes following a 
AFRT-CB protocol, the limitations of this study are acknowledged with small numbers 
having restricted the ability to make generalisations about long-term function from this 
population. While the aim of this study was to examine the functional outcomes and explore 
the patient perspective of their treatment and subsequent barriers to intake, the lack of 
videofluoroscopic assessment at this 2 year time point does not allow comment on long-term 
swallowing physiology. Although not the focus of this study, the assimilation toward 
pretreatment patient-rated function ( as scored by validated questionnaires) despite ongoing 
reports of body function impairment may also be related to the contextual personal and 
environmental factors, as well as premorbid body functions of optimism and other 
temperament and personality functions, outlined by the ICF. Factors such as support and 
relationships, personal attitudes, and access to ongoing services from health professionals 
may facilitate some individuals to consider their function in a more positive way. Although 
not within the scope of the current study, the functional impact these long-term barriers to 
oral intake have on spouses and family members is also unknown. Often close family are 
involved in food selection and preparation, and may report negative changes in cooking, 
mealtime routines, reduced social eating with their family, and greater stress related to caring 
for their family member who is a long-term HNC survivor. This notion of “third-party 
disability” (49) is an area which needs further investigation, as well as the impact of 
contextual factors on recovery and perception of impairment.  
 
The current study has revealed the lasting impact of AFRT-CB on salivary and swallowing 
function at 2 years post-treatment, with the majority requiring ongoing dietary restriction, 
reporting a significant negative impact on the physical aspects of swallowing, which has 
contributed to activity limitation and participation restriction in eating. In general weight that 
was lost from baseline to 6 months, as a result of treatment side effects, had not been regained 
2 years after treatment was completed. Several facilitatory strategies to manage their 
impairments were reported by participants. Overall, at 2 years post-treatment, participants 
rated that their global functioning had returned to pretreatment levels, possibly an indication 
of adjustment. The long-term swallowing and nutritional dysfunction highlights the need for 
ongoing speech pathology, dietetic, social work, and psychology involvement in assisting 
patients to return to their pretreatment oral intake, regain weight lost as a result of treatment, 
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01 82 M T1N0 L pharyngeal wall I Ex Current 
02 63 M T2N0 supraglottis II Current Current 
03 79 M T3N0 BOT  III Ex Current 
04 72 M T2N0 L tonsil  II Never Current 
05 69 F T2N2b L tonsil  IV Ex N/Ad 
06 70 M T1N0 L tonsil  I Ex Current 
07 69 M T2N1 R tonsil  III Ex Current 
08 59 M T2N0 R supraglottis II Ex Current 
09 59 M T1N2a R tonsil IV Never Current 
10 58 F T3N0 R tonsil III Current Current 
11 53 M T2N1 R tonsil III Never Current 
12 54 M T1N2a R tonsil IV Never Current 
a M = male,  F = female. b T = T stage, N = N stage. c L = left, R = right. d Information regarding alcohol history not 
reported 
Table 2. Toxicity, functional swallowing, participant-rated functional impact, and weight  at 2 years post-treatment with AFRT-CB compared 
with pretreatment and 6 months post-treatment 
Post-hoc Wilcoxon signed 
rank/Paired t-test 
Pre versus  
2 years 
















Z/t P Z/t p 
CTCAEa Xerostomia 0 (0) 1.08 (0.7) 1.67 (0.5) -3.18 <0.01 -2.33 0.02 
 Dysphagia 0 (0) 0.92 (0.7) 1.6 (0.7) -3.13 <0.01 -2.82 0.01 
RBHOMSb  8.67 (0.78) 7.83 (0.4) 7.33 (0.8) -3.1 <0.01 -3.0 <0.01 
MDADIc Global   83.6 (17.5) 70 (21.7) 75 (33.2) 0.86 0.39 -1.0 0.32 
 Emotional    87.9 (9.3) 77.8 (18.4) 78.5 (18.4) 1.56 1.12 -0.28 0.78 
 Functional 86.2 (13.2) 78.3 (14.5) 81 (17.6) 1.43 0.15 -0.67 0.5 
 Physical 81.4 (16.2) 70.2 (12.8) 70.8 (18.2) 2.08 0.04 -0.23 0.78 
FACT-H&Nd Physical (0-28) 24.5 (4.6) 22.3 (6.1) 23.9 0.94 0.35 -1.5 0.12 
 Social/ Family (0-28) 24.1 (4.9) 21.9 (7.7) 22.2 (6.1) 1.56 0.12 -0.43 0.66 
 Emotional (0-24) 20.1 (3) 21.3 (2.6) 20.5 (3.5) -0.31 0.76 0.48 0.63 
 Functional (0-28) 22.1 (4.2) 20.7 (5.8) 22.3 (5.5) 0.05 0.96 -1.93 0.05 
 Head/Neck Specific (0-48) 38.5 (5.6) 31 (6.7) 35.8 (6.7) 1.56 0.12 -2.4 0.02 
 Overall (0-156) 129.7 (13.4) 120.4 (20.3) 123.8 (18) 1.89 0.06 -1.22 0.22 
Weight (kg)  82.5kg (24.3) 70.2kg (20.2) 71.6kg (21.5) 3.17 < 0.01 -0.23 0.59 
Note. Italicized values refer to significant results. aCommon Toxicity Criteria of Adverse Events version 3.0. bRoyal Brisbane Hospital Outcome Measure for Swallowing. 
cM. D. Anderson Dysphagia Inventory. dFunctional Assessment of Cancer Therapy Additional Concerns for Head and Neck. 
Table 3. Frequency of patient reported barriers to oral intake in relation to body impairments, and activity limitations/participation restrictions 
as classified by the ICF, reported by participants at 2 years post-treatment with AFRT-CB 
 
Patient reported barrier  % Impairment in body function Activity Limitation /  
Participation Restriction 
Dry mouth 92% Salivation Eating 
Taste problems 75% Taste function Eating 
Food gets stuck 75% Pharyngeal swallowing Eating 
Appetite problems 58% Energy and drive (appetite)  Looking after one’s health, Eating 
Cough with food/fluid 50% Pharyngeal swallowing Eating 
Difficulty enjoying meals 50% Emotional functions or contextual factor Looking after one’s self, Eating 
Sticky saliva 42% Salivation Eating 
Chewing difficulties 33% Chewing Eating 
Ulcers 25% Oral swallowing Eating 
Jaw stiffness 25% Mobility of joint functions Eating 
Thrush 17% Oral swallowing Eating 
Fatigue 17% Energy and drive (energy level) Carrying out daily routine 
Painful swallowing 17% Sensation of pain (pain in head and neck) Eating 
Sense of smell changed 8% Smell function Eating 
Neck stiffness 8% Mobility of joint functions Eating 
FIGURES  
 























Figure 2.  Frequency of patient-reported strategies used to overcome swallow-related 
















































Figure 3.  Frequency of patient-reported strategies used to maintain weight at 2 years 
post-treatment with AFRT-CB 
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